PDS Biotechnology (NASDAQ:PDSB) reported first-quarter financial results on Wednesday.
The transcript from the company’s first-quarter earnings call has been provided below
Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/apis/ to learn more. The full earnings call is available at https://viavid.
Summary PDS Biotechnology reported a net loss of $7.3 million for Q1 2026, an improvement from $8.5 million in Q1 2025, with reduced research and development and general administrative expenses. The company made significant progress in its clinical programs, notably amending the versatile 003 trial to include progression-free survival as a primary endpoint, potentially reducing trial duration and costs. PDS Biotechnology strengthened its intellectual property with new patents for PDS0101 in the US and Japan, extending market protection into the 2040s.